PharmaCyte Biotech Inc. (NASDAQ:PMCB) shares skyrocketed 67.8% on Tuesday after the company announced it had completed the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), significantly bolstering its liquidity.
The sale is projected to lift PharmaCyte’s combined cash and marketable securities to roughly $20 million, up from $13.3 million reported as of July 31, 2025. Management said the move demonstrates the strength of its capital allocation strategy while preserving a cautious approach to portfolio risk.
“Our successful monetization of the Femasys position demonstrates the effectiveness of our strategic and disciplined capital allocation approach,” said Josh Silverman, PharmaCyte Chief Executive Officer. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation.”
According to the company’s latest 10Q filing, PharmaCyte now holds about $25 million in marketable securities—on top of nearly $20 million in cash that includes proceeds from the divestiture. Prior to Tuesday’s rally, the stock had been trading around $0.65 per share, with approximately 6.8 million shares outstanding.
Looking ahead, PharmaCyte said it will continue searching for investments that enhance long-term shareholder value while maintaining disciplined operational execution.